Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease
- DOI
- 10.1186/s12890-026-04347-3
- Published
- 2026-05-19
- Container
- BMC Pulmonary Medicine
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12890-026-04347-3,
title = {Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease},
author = {Shiho Goda and Tadaaki Yamada and Yasuhiro Goto and Sayaka Uda and Akira Nakao and Shinsuke Shiotsu and Yuji Kukida and Keiko Tanimura and Akifumi Miyamoto and Yuki Imasato and Asuka Okada and Isao Hasegawa and Koji Date and Yohei Matsui and Shoki Morito and Noeru Inokuchi and Shuji Osugi and Hayato Kawachi and Naoya Nishioka and Masahiro Iwasaku and Shinsaku Tokuda and Tomohiro Handa and Koichi Takayama},
year = {2026},
journal = {BMC Pulmonary Medicine},
doi = {10.1186/s12890-026-04347-3},
url = {https://doi.org/10.1186/s12890-026-04347-3}
}RIS
TY - JOUR TI - Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease AU - Shiho Goda AU - Tadaaki Yamada AU - Yasuhiro Goto AU - Sayaka Uda AU - Akira Nakao AU - Shinsuke Shiotsu AU - Yuji Kukida AU - Keiko Tanimura AU - Akifumi Miyamoto AU - Yuki Imasato AU - Asuka Okada AU - Isao Hasegawa AU - Koji Date AU - Yohei Matsui AU - Shoki Morito AU - Noeru Inokuchi AU - Shuji Osugi AU - Hayato Kawachi AU - Naoya Nishioka AU - Masahiro Iwasaku AU - Shinsaku Tokuda AU - Tomohiro Handa AU - Koichi Takayama PY - 2026 JO - BMC Pulmonary Medicine DO - 10.1186/s12890-026-04347-3 UR - https://doi.org/10.1186/s12890-026-04347-3 ER -
APA
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., Okada, A., Hasegawa, I., Date, K., Matsui, Y., Morito, S., Inokuchi, N., Osugi, S., Kawachi, H., Nishioka, N., Iwasaku, M., Tokuda, S., Handa, T., & Takayama, K. (2026). Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-026-04347-3
Source records
- crossref · retrieved 2026-09-26T18:50:10.039Z